GSI526

GSI526 (1-10000 nM; 24 h) induces dose-dependent degradation of IRAK4 in HEK293T cells with a DC₅₀ of 50.89 nM and a Dmax greater than 80%^[1].
GSI526 (0.01-30 μM; 24 h) exhibits no cytotoxicity in THP-1 cells at concentrations up to 30 μM following 24 h incubation^[1].
GSI526 (0.01-30 μM; 48 h) exhibits no cytotoxicity in HEK293T cells at concentrations up to 30 μM following 48 h incubation^[1].
GSI526 (1000 nM; 8 h) exhibits marked selectivity toward IRAK4 in THP-1 cells, with IRAK4 showing a statistically significant downregulation following 8 h treatment with 1000 nM GSI526^[1].
GSI526 (1-5 μM; 1 h pretreatment, followed by 6 h LPS stimulation) inhibits LPS-induced activation of the IRAK4-NF-κB/MAPK signaling pathway in THP-1 cells via degradation of IRAK4^[1].
GSI526 (0.3-3 μM; 1 h pretreatment, followed by 24 h LPS stimulation) dose-dependently inhibits LPS-induced expression of TNF-α and CXCL8 in THP-1 cells via suppression of the IRAK4-NF-κB/MAPK signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.